Results 231 to 240 of about 227,343 (293)

Light Physical Activity and All-Cause Mortality in US Adults Across Cardiovascular-Kidney-Metabolic Syndrome Stages. [PDF]

J Am Heart Assoc
Sartini J, Rooney MR, Schrack JA, McEvoy JW, Ndumele CE, Zeger S, Selvin E, Fang M.   +7 more
europepmc   +1 more source

The potential for biased signalling in the P2Y receptor family of GPCRs

British Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk, Simon Pitchford, Graham Ladds   +2 more
wiley   +1 more source

Air pollution promotes the onset and progression of cardiovascular-kidney-metabolic syndrome: a nationwide prospective cohort study. [PDF]

BMC Public Health
Gui C, Xiao Z, Li M, Xu J.
europepmc   +1 more source

Validity of the elastase assay in intensive care medicine [PDF]

, 1988
Fritz, Hans, Jochum, Marianne, Lang, H., Redl, H., Redl, H., Schlag, G.   +5 more
core  

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

The Role of Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Cardiovascular-Kidney-Metabolic Syndrome. [PDF]

JACC Adv
Kumar S, Anderson JE, Coviello A, Lopez-Jimenez F, Bakris GL.   +4 more
europepmc   +1 more source

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

British Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia, Lisa Zimmer, Lena Lampe, Dimitra Vlachopoulou, Matthias Totzeck, Tienush Rassaf, Raluca I. Mincu   +6 more
wiley   +1 more source